Oppenheimer Maintains Outperform Rating On Pluristem Therapeutics

According to Oppenheimer, Pluristem Therapeutics

Outperform rating is maintained. Oppenheimer said that yesterday, Aastrom Biosciences (ASTM, $3.04, Not Rated) reported top-line results for its Phase II study called RESTORE-CLI. “The trial investigated administration of expanded autologous mononuclear cells for the treatment of critical limb ischemia (

) and used a primary endpoint of time to treatment failure at 12 months. The study met its primary endpoint and Aastrom is currently finalizing its discussions with the FDA for a Special Protocol Assessment, and plans to commence Phase III shortly thereafter. RESTORE-CLI was not powered to show statistically significant improvement in amputation-free survival, but we anticipate investors will focus on this result once the data is presented. This is the third update from this study, and complete results are anticipated at a medical meeting.” Pluristem Therapeutics closed yesterday at $2.68.